<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4126">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04694482</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-19-psychiatry</org_study_id>
    <nct_id>NCT04694482</nct_id>
  </id_info>
  <brief_title>The Impact of the COVID-19 (SARS-CoV-2 Disease) on Psychopathology</brief_title>
  <official_title>The Psychopathological Impact of the SARS-CoV-2 Epidemic on Subjects Suffering From Mental Disorders: Data From ASST Monza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera San Gerardo di Monza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Milano Bicocca</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The outbreak of the SARS-CoV-2 pandemic may be considered a traumatic phenomenon.&#xD;
&#xD;
      In a sample of subjects suffering from different psychiatric disorders, psychopathological&#xD;
      status and Post-Traumatic Stress Disorder (PTSD) symptoms over time are assessed using&#xD;
      specific psychometric scales. In a sample of healthy controls PTSD symptoms are evaluated by&#xD;
      Impact of Event Scale Revised (IES-R) and compared to patients' scores.&#xD;
&#xD;
      We hypothesize that a significant number of psychiatric outpatients have experienced a&#xD;
      clinical psychopathological worsening and a greater prevalence of PTSD symptoms compared to&#xD;
      the general population. The study of the potential psychopathological changes could represent&#xD;
      a useful contribution to deepen the understanding of psychological consequences of the&#xD;
      pandemic.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SARS-CoV-2 epidemic is a worldwide phenomenon which generated fear, anxiety, depression and&#xD;
      PTSD symptoms, as a consequence of the high number of deaths and the restricted measures&#xD;
      adopted by the Italian Government to stem the spread of the virus.&#xD;
&#xD;
      The aims of the study are: (1) to investigate potential psychopathological changes over time&#xD;
      in a sample of patients affected by different psychiatric disorders (schizophrenia, bipolar&#xD;
      disorder, major depression, anxiety/Obsessive-Compulsive Disorder (OCD), personality&#xD;
      disorders); (2) to compare patients and healthy controls in terms of post-traumatic symptoms.&#xD;
&#xD;
      Outpatients affected by different psychiatric disorders are recruited during their routine&#xD;
      visits and demographic/clinical variables are collected from their medical records.&#xD;
&#xD;
      Psychopathological status and PTSD symptoms are retrospectively assessed using specific&#xD;
      psychometric scales, such as Brief Psychiatry Rating Scale (BPRS), Clinical Global Impression&#xD;
      (CGI), Disability Scale (DISS), Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression&#xD;
      Rating Scale (HAM-D), Montgomery and Asberg Depression Rating Scale (MADRS), Young Mania&#xD;
      Rating Scale (YMRS), Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), IES-R.&#xD;
&#xD;
      The assessment is performed over time at three time points: T0 corresponding to the outbreak&#xD;
      of the pandemic (January-February 2020), T1 which was the lockdown period (March-April 2020)&#xD;
      and T2 corresponding to the reopening and restarting (May-June 2020).&#xD;
&#xD;
      Descriptive analyses of the whole sample will be performed. Then, mixed linear regression&#xD;
      models will be run to investigate the change over time in patients' psychometric scores and&#xD;
      whether it differs among different diagnostic groups. Moreover, same analyses will be&#xD;
      performed to compare patients and healthy subjects in terms of change of IES-R scores over&#xD;
      time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Brief Psychiatric Rating Scale (BPRS)</measure>
    <time_frame>Two months</time_frame>
    <description>Range 0-126. Higher scores mean worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression (CGI) severity subscale</measure>
    <time_frame>Two months</time_frame>
    <description>Range 0-7. Higher scores mean worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression (CGI) improvement subscale</measure>
    <time_frame>Two months</time_frame>
    <description>Range 0-7. Higher scores mean worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hamilton Anxiety Scale (HAM-A)</measure>
    <time_frame>Two months</time_frame>
    <description>Range 0-56. Higher scores mean worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of Event Scale - Revised version (IES-R)</measure>
    <time_frame>Two months</time_frame>
    <description>Range 0-88. Higher scores mean worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disability Scale (DISS)</measure>
    <time_frame>Two months</time_frame>
    <description>Range 0-10. Higher scores mean worse outcome. Support subscale: Range 0-100. Higher scores mean better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (HAM-D)</measure>
    <time_frame>Two months</time_frame>
    <description>Range 0-67. Higher scores mean worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery and Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Two months</time_frame>
    <description>Range 0-60. Higher scores mean worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Young Mania Rating Scale (YMRS)</measure>
    <time_frame>Two months</time_frame>
    <description>Range 0-56. Higher scores mean worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)</measure>
    <time_frame>Two months</time_frame>
    <description>Range 0-40. Higher scores mean worse outcome.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Psychosis;Schizophrenic</condition>
  <condition>Personality Disorders</condition>
  <condition>Mood Disorders</condition>
  <condition>Anxiety Disorders</condition>
  <condition>Post Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>psychiatric patients</arm_group_label>
    <description>Psychometric scales</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <description>Psychometric scales</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Psychometric scale administration</intervention_name>
    <description>PTSD symptoms are assessed using a specific scale (IES-R) and compared between the two groups</description>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_label>psychiatric patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Psychiatric outpatients and healthy controls resident in the same geographic area as the&#xD;
        patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  understanding of the Italian language&#xD;
&#xD;
          -  ability to understand and sign written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe mental retardation&#xD;
&#xD;
          -  pregnancy or post-partum period&#xD;
&#xD;
          -  severe or chronic medical condition&#xD;
&#xD;
          -  health workers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrizia Colmegna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASST Monza</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alice Caldiroli, MD</last_name>
    <phone>+393495009941</phone>
    <email>a.caldiroli@asst-monza.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Milan Bicocca - Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Caldiroli, MD</last_name>
      <phone>+393495009941</phone>
      <email>a.caldiroli@asst-monza.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Milano Bicocca</investigator_affiliation>
    <investigator_full_name>Fabrizia Colmegna</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

